SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience-Reference-Cited by-同舟云学术

SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience

Published:2019-05-15 Issue:5 Volume:14 Page:e0215783
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Mangia Alessandra^ORCID,Piazzolla Valeria,Giannelli Anna,Visaggi Egidio,Minerva Nicola,Palmieri Vincenzo,Carraturo Immacolata,Potenza Domenico,Napoli Nicola,Lauletta Gianfranco,Tagarielli Vincenzo,Santoro Rosanna,Piccigallo Ernesto,De Gioia Sergio,Chimenti Angelo,Cuccorese Giuseppe,Metrangolo Antonio,Mazzola Michele,Agostinacchio Ernesto,Mennea Giuseppe,Sabbà Carlo,Cela Marina,Copetti Massimiliano,Losappio Ruggiero

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis;Global health sector strategy on viral hepatitis, 2016–2021: towards ending viral hepatitis,2016

2. EPCLUSA, Gilead Sciences Inc.EPCLUSA (sofosbuvir and velpatasvir) tablets for oral use. US prescribing information Foster City, CA. Revised: August 2017

3. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection;JJ Feld;N Engl J Med,2015

4. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection;G Foster;N Engl J Med,2015

5. AASLD/IDSA. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. https://hcvguidelines.org./Accessed 15 March, 2018

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Influence of Treatment With Sofosbuvir/Velpatasvir on Children’s Growth—Results of the PANDAA-PED Study;Pediatric Infectious Disease Journal;2024-09-04

2. Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years;Gastroenterología y Hepatología;2024-05

3. Profile of Sofosbuvir and Velpatasvir Combination in the Treatment of Chronic Hepatitis C in Children and Adolescents: Current Evidence;Therapeutics and Clinical Risk Management;2024-01

4. Effectiveness of second-generation direct-acting antivirals in patients infected with hepatitis c virus and factors associated with a nonsustained virological response;Brazilian Journal of Pharmaceutical Sciences;2024

5. Hepatitis C Virus Infection in the Elderly in the Era of Direct-Acting Antivirals: Evidence from Clinical Trials and Real Life;Tropical Medicine and Infectious Disease;2023-11-18